A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.

PURPOSE: We have developed a statistical prediction model for prostate cancer based on four kallikrein markers in blood: total, free, and intact prostate-specific antigen (PSA), and kallikrein-related peptidase 2 (hK2). Although this model accurately predicts the result of biopsy in unscreened men,...

Full description

Bibliographic Details
Main Authors:	Vickers, A, Cronin, A, Roobol, M, Savage, C, Peltola, M, Pettersson, K, Scardino, P, Schröder, F, Lilja, H
Format:	Journal article
Language:	English
Published:	2010

Similar Items

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
by: Gupta, A, et al.
Published: (2010)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
by: Vickers, A, et al.
Published: (2010)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
by: Scardino Peter T, et al.
Published: (2008-07-01)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
by: Vickers, A, et al.
Published: (2011)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
by: Benchikh, A, et al.
Published: (2010)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
by: Villers Arnauld, et al.
Published: (2010-11-01)

Screening for prostate cancer: early detection or overdetection?
by: Vickers, A, et al.
Published: (2012)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
by: Christensson, A, et al.
Published: (2011)

Screening for prostate cancer: an update.
by: Shariat, S, et al.
Published: (2008)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
by: Savage, C, et al.
Published: (2010)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
by: Carlsson, S, et al.
Published: (2012)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
by: Klein, R, et al.
Published: (2010)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Urological cancer: Time for another rethink on prostate cancer screening.
by: Vickers, A, et al.
Published: (2012)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
by: Wenske, S, et al.
Published: (2009)

Prostate cancer screening in the elderly: A yes or no issue? Long term follow-up data from ERSPC Rotterdam
by: M.J. Roobol, et al.
Published: (2020-07-01)

Five genetic variants associated with prostate cancer.
by: Vickers, A, et al.
Published: (2008)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
by: Becker, C, et al.
Published: (2000)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
by: Ylikoski, A, et al.
Published: (2001)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
by: Haese, A, et al.
Published: (2003)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
by: Lilja, H, et al.
Published: (2007)

Prostate cancer screening in Europe and Asia
by: Kai Zhang, et al.
Published: (2017-04-01)

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
by: Vickers, A, et al.
Published: (2010)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
by: Janssen, S, et al.
Published: (2004)

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
by: Roobol, M, et al.
Published: (2009)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
by: Vickers, A, et al.
Published: (2007)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
by: Sebastiaan Remmers, et al.
Published: (2023-05-01)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
by: Klein, R, et al.
Published: (2012)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
by: Ylikoski, A, et al.
Published: (2002)